Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein

Name: Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein
Brand: Puweituo Bio
SKU: KRASG12V-HP003

Catalog numberKRASG12V-HP003

HumanE. coliMolecule · MHCMolecular weight · 35.26 kDa

Product introduction

Recombinant Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide (accession: NP_002107.3(HLA-A*03:01) & P61769(B2M) &VVVGAVGVGK).

Product details

Molecular aliases: MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Protein length: Gly25-Thr305
Expression system: E. coli
Molecular weight: The protein has a predicted MW of 35.26 kDa (HLA-A*03:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Purity: > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin: Less than 1 EU per μg by the LAL method.
Formulation: Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
Storage: Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data display

Bis-Tris PAGE Data — Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC Data — The purity of Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer is greater than 95% as determined by SEC-HPLC.

BLI Data — Loaded Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody, hFc Tag on ProA-Biosensor can bind HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK), His Tag with an affinity constant of 0.92 µM as determined in BLI assay. (QC Test)

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

References

1.(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

加载中…

Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein

Catalog numberKRASG12V-HP003

HumanE. coliMolecule · MHCMolecular weight · 35.26 kDa

Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

BLI

BLI Data

Background

References

Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein

Product introduction

Product details

Data display

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

BLI

BLI Data

Background

References